Global Partners L.P. (GLP)
NYSE NYSE Primary Summary
GLP Chart
Novo Nordisk: Ignored GLP-1 Leader Is Now A Deep Value Play
NVO's bottom has finally materialized after the painful halving from June 2024 peaks, as the GLP-1 compounding/supply headwinds moderate. This is significantly aided by the expanded partnership with numerous legacy healthcare/telehealth players, with H2 '25 likely to bring forth sequentially improved performance. Despite the management's lowered FY2025 guidance, NVO's expanded capacity supports the promising consensus forward estimates, with the stock likely to outperform from current oversold levels.
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40 in a key secondary endpoint The safety profile of orforglipron was consistent with the established GLP-1 class INDIANAPOLIS , June 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Orforglipron is the first oral small molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial.
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modifications Treatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Unique, dual mechanism, including GLP-2 activity, designed to target obesity-related comorbid conditions driven by low-grade inflammation Copenhagen, Denmark, June 18, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Global Partners L.P. Dividends
| GLP In 1 month Estimated | Quarterly | $0.74 Per Share |
| GLP 1 month ago Paid | Quarterly | $0.74 Per Share |
| GLP 4 months ago Paid | Quarterly | $0.74 Per Share |
| GLP 7 months ago Paid | Quarterly | $0.73 Per Share |
| GLP 10 months ago Paid | Quarterly | $0.72 Per Share |
| GLP 8 May 2024 Paid | Quarterly | $0.71 Per Share |
Global Partners L.P. Earnings
| 6 May 2025 Date | | - Cons. EPS | 0.36 EPS |
| 26 Feb 2025 Date | | 0.24 Cons. EPS | 0.52 EPS |
| 8 Nov 2024 Date | | 1.57 Cons. EPS | 1.17 EPS |
| 7 Nov 2024 Date | | 1.57 Cons. EPS | - EPS |
| 7 Aug 2024 Date | | 1.5 Cons. EPS | 1.1 EPS |
| GLP In 1 month Estimated | Quarterly | $0.74 Per Share |
| GLP 1 month ago Paid | Quarterly | $0.74 Per Share |
| GLP 4 months ago Paid | Quarterly | $0.74 Per Share |
| GLP 7 months ago Paid | Quarterly | $0.73 Per Share |
| GLP 10 months ago Paid | Quarterly | $0.72 Per Share |
| GLP 8 May 2024 Paid | Quarterly | $0.71 Per Share |
| 6 May 2025 Date | | - Cons. EPS | 0.36 EPS |
| 26 Feb 2025 Date | | 0.24 Cons. EPS | 0.52 EPS |
| 8 Nov 2024 Date | | 1.57 Cons. EPS | 1.17 EPS |
| 7 Nov 2024 Date | | 1.57 Cons. EPS | - EPS |
| 7 Aug 2024 Date | | 1.5 Cons. EPS | 1.1 EPS |
Global Partners L.P. (GLP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Global Partners L.P. ever had a stock split?
Global Partners L.P. Profile
| Oil & Gas Midstream Industry | Energy Sector | Mr. Eric S. Slifka CEO | NYSE Exchange | 37946R109 Cusip |
| US Country | 3,300 Employees | 9 May 2025 Last Dividend | - Last Split | 29 Sep 2005 IPO Date |
Overview
Global Partners LP is a diverse energy supply company established in 2005, headquartered in Waltham, Massachusetts. The company's core operations encompass the purchase, sale, aggregation, blending, storage, and logistics management of a wide range of petroleum products and renewable fuels. It operates through three primary segments: Wholesale, Gasoline Distribution and Station Operations, and Commercial. By leveraging a comprehensive network of railcars, barges, trucks, and pipelines, Global Partners LP ensures the efficient transportation and delivery of its products to a broad spectrum of wholesalers, retailers, and commercial customers across various sectors.
Products and Services
- Wholesale
In its Wholesale segment, the company focuses on the distribution of home heating oil, both branded and unbranded gasoline and gasoline blendstocks, diesel, kerosene, and residual oil. It targets home heating oil and propane retailers along with wholesale distributors. The transportation of these products is facilitated through an extensive network of railcars, barges, trucks, and pipelines, ensuring timely and safe delivery.
- Gasoline Distribution and Station Operations
Through the Gasoline Distribution and Station Operations segment, Global Partners LP engages in the sale of branded and unbranded gasoline to operators of gasoline stations and sub-jobbers. It also manages gasoline stations and convenience stores, offering a range of services including car wash, lottery, and ATM facilities. Additionally, the company’s operations include the leasing of gasoline stations to third parties.
- Commercial
The Commercial segment of the business caters to a diverse clientele including public sector entities, commercial industries, and industrial end-users. It supplies unbranded gasoline, home heating oil, diesel, kerosene, residual oil, and bunker fuel. Global Partners LP is also known for selling custom blended fuels tailored to specific customer requirements. This segment underscores the company’s ability to meet the specialized needs of its commercial and industrial customers.
- Transportation of Petroleum Products and Renewable Fuels
Besides its main trading activities, Global Partners LP is significantly involved in the transportation sector, specifically in the movement of petroleum products and renewable fuels. Leveraging rail transportation, the company facilitates the efficient movement of these products from the mid-continent region of the United States and Canada, highlighting its logistical capabilities and commitment to ensuring a steady supply of energy resources.
Contact Information
